Category: biotech

.AbbVie has actually gone back to the resource of its own antipsychotic goliath Vraylar searching for one more hit, paying for $25 million beforehand to

.Merely a couple of short full weeks after winning an FDA Fast Track tag for its investigational BTK degrader in specific blood stream cancers cells,

.On the very same day that some Parkinson’s disease medications are actually being brought into question, AbbVie has revealed that its late-stage monotherapy candidate has

.AstraZeneca has made use of expert system to create a distinct biomarker for its own Daiichi Sankyo-partnered datopotamab deruxtecan (Dato-DXd), wishing to differentiate the antibody-drug

.Monopar Therapeutics is recouping a drug from the scrap heap of AstraZeneca’s unusual disease pipe. It has certified ALXN-1840, a prospect for the therapy of